Immunocore Holdings plc Gains Losses On Exchange Differences On Translation Recognised In Profit Or Loss
Immunocore Holdings plc (IMCR) reported Gains Losses On Exchange Differences On Translation Recognised In Profit Or Loss of GBP 122.00 thousand for the 12-month period ending 2022-12-31, per its 20-F filed 2023-03-01.
Discontinued › Expense Statement › Operating Expenses
ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss · last filed 2023-03-01
| Period end | Gains Losses On Exchange Differences On Translation Recognised In Profit Or Loss 12 month | Gains Losses On Exchange Differences On Translation Recognised In Profit Or Loss 12 month as first filed |
|---|---|---|
| 2022-12-31 | 122.00K GBP 20-F · filed 2023-03-01 | |
| 2021-12-31 | 0.00 GBP 20-F · filed 2023-03-01 | -277.00K GBP 20-F · filed 2022-03-03 |
| 2020-12-31 | 477.00K GBP 20-F · filed 2022-03-03 | |
| 2019-12-31 | 189.00K GBP 20-F · filed 2022-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |